News
MIMETAS and Yamaha Motor Sign Joint Marketing Agreement to Advance Automated Human Disease Model Applications for Drug Development
November 29, 2023
Strategic joint marketing agreement MIMETAS and Yamaha Motor.
Read more
First Patient with Chronic Hepatitis B Dosed with ISA104 in First-in-Human Phase 1 Study
August 31, 2023
Study by Erasmus MC marks first clinical development milestone for ISA104 immunotherapeutic treatment of chronic hepatitis B in...
Read more
Sapreme Appoints Experienced Industry Executives, Dr. Jeanne Bolger and Dr. Andre Hoekema, to its Board of Directors
July 20, 2023
Jeanne Bolger and Andre Hoekema Sapreme Board of Directors
Read more
MIMETAS and Astellas Expand Partnership to Include Automation and Application Support
June 20, 2023
MIMETAS and Astellas expand partnership.
Read more
MIMETAS and Astellas Enter into Strategic Partnership on Immuno-Oncology
March 28, 2023
Strategic Partnership Mimetas - Astellas
Read more
Modra Pharmaceuticals Announces U.S. Patent Issuance for ModraDoc006/r
March 16, 2023
U.S. Patent and Trademark Office (USPTO) has issued to Modra U.S. Patent No. 11,571,408, covering the use of its oral taxane th...
Read more
CliCr® and CliCr® derivatives are available via Iris Biotech GmbH
January 26, 2023
Iris Biotech sells CliCr® and CliCr® reagents.
Read more
Lonza Collaborates with Cristal Therapeutics and McSAF to Expand Bioconjugates Offering
January 17, 2023
- Cristal Therapeutic CliCr® technology and McSAF Inside® technology will be integrated into the Lonza Bioconjugation Toolbox...
Read more
MIMETAS Elected Most Innovative Company of the Netherlands
November 02, 2022
Mimetas is the winner of the Dutch Innovation Award 2022.
Read more
Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering
October 18, 2022
Synaffix B.V. today announces that it has signed a licensing agreement with Cristal Therapeutics to gain access to its CliCr® m...
Read more
